Regorafenib – Targeted Cancer Drug

Regorafenib - Targeted Cancer Drug

The most effective treatment for Crohn’s disease (CD) to-date is Regorafenib. Regorafenib, marketed under the trade name Stivarga, is orally non-intravenous multi-kinase inhibitors, or kinase inhibitors, designed to target oncogenes, stromal or angiogenic receptors. Regorafenib exhibits anti-angiogenesis activity because of its dual selective VEGFR2 -TIE2 tyrosine receptor inhibitory activity.

Patients with Crohn’s disease have difficulty draining toxins from the body and this leads to severe inflammation, fever, and other symptoms. Patients with moderate or mild chronic liver disease are often treated with immunosuppressive medications such as Prednisone, Nuprin, and Cortislim to reduce the liver’s production of cytokines and free radicals. Patients with Crohn’s often experience severe adverse side effects from these medications that include fatigue, depression, and weight gain. In fact, patients experience a decreased appetite, weight loss, increased appetite, diarrhea, nausea, and abdominal bloating when taking regorafenib.

Some patients take regorafenib and find that they experience nausea, vomiting, constipation, diarrhea, loss of appetite, or abnormal tastes in the mouth. Such adverse events can occur if the drug is not metabolized properly by the gastrointestinal tract. For example, some patients experience an increase in fluid and electrolyte retention, intestinal contractility, increased bowel frequency or altered bowel reflexes. Because of the potential for serious adverse events, patients should be monitored carefully if taking Regorafenib and if pregnant.

One of the most common reactions to regorafenib is a mild to moderate hand-foot skin reaction. A rash similar to eczema may form in some patients after using the drug. It usually does not cause pain, but the rash can be itchy and irritated. If rash develops, discontinue use and contact doctor right away.

In rare cases, patients experience severe allergic reactions to regorafenib. Patients can develop anaphylactic shock after ingesting a dose of the drug. The blood-clotting ability of the body is impaired when crtitoxoid drugs are ingested, which is why emergency treatment should be obtained immediately if anaphylactic shock occurs. Because of the potential risk for anaphylactic shock, few patients should not take this medication with epinephrine.

Regorafenib is one of the few prescription drugs that have no contraindications. This makes it ideal for use in both early and advanced cancer therapies. This medical treatment has shown promising results for several types of cancers including breast and cervical cancer. For this reason, it is used primarily on the prostate. The combination of a solid dose of regorafenib and multiple doses of cisplatin has proven extremely effective in treating various types of cancer. You can get more information from